Latest Cancer Diagnostics News

Page 6 of 12
BCAL Diagnostics is preparing to launch its Avantect® pancreatic and ovarian cancer blood tests in Australia by January 2026, following key regulatory approvals and promising clinical data. The company also broadens the reach of its BREASTESTplus™ breast cancer test, targeting a larger segment of women with dense breast tissue.
Ada Torres
Ada Torres
19 Nov 2025
Cleo Diagnostics has identified a significantly larger U.S. patient population for its pre-surgical ovarian cancer test, expanding its commercial opportunity ahead of next year’s market entry.
Ada Torres
Ada Torres
6 Nov 2025
Imagion Biosystems reports encouraging findings from its Wayne State University collaboration, supporting a lower dose for its MagSense® HER2 imaging agent ahead of a planned FDA IND submission in Q4 2025.
Ada Torres
Ada Torres
5 Nov 2025
TrivarX Limited has exercised its option to acquire the innovative Stabl-Im brain imaging technology, aiming to revolutionize early detection of brain tumours pending shareholder approval.
Ada Torres
Ada Torres
5 Nov 2025
Clarity Pharmaceuticals has bolstered its financial position with a $203 million institutional placement and reported positive Phase II trial results for its lead prostate cancer diagnostic, Cu-SAR-bisPSMA. The company also expanded its pipeline with promising preclinical data on a pan-cancer agent and secured a key copper-67 supply agreement to support future commercialisation.
Ada Torres
Ada Torres
31 Oct 2025
BCAL Diagnostics has secured key partnerships and a $10 million convertible note facility to expand its cancer detection tests across Australia and New Zealand, marking steady commercial progress in Q3 2025.
Ada Torres
Ada Torres
31 Oct 2025
Cleo Diagnostics has successfully completed Stage 1 of the Medical Device Single Audit Program, marking a significant step toward FDA submission and global commercialisation of its ovarian cancer test.
Ada Torres
Ada Torres
30 Oct 2025
Rhythm Biosciences reports strong Q1 FY26 progress, securing strategic partnerships and advancing commercial readiness for its ColoSTAT® colorectal cancer test alongside robust growth in its geneType platform.
Ada Torres
Ada Torres
29 Oct 2025
INOVIQ Limited has raised $9.5 million to advance its pioneering ovarian cancer screening test and CAR-exosome therapeutic programs, backed by strong preclinical data and strategic partnerships.
Ada Torres
Ada Torres
29 Oct 2025
BCAL Diagnostics has launched a $10 million convertible note facility, with $5 million already committed, to strengthen its capital position and accelerate commercialisation of its cancer detection technologies.
Ada Torres
Ada Torres
20 Oct 2025
BCAL Diagnostics has established a $10 million convertible note facility, with $5 million already committed, to accelerate its cancer detection technologies and commercial milestones.
Ada Torres
Ada Torres
20 Oct 2025
INOVIQ Limited has completed a $9.5 million placement to institutional investors and launched a $2 million Share Purchase Plan for existing shareholders, aiming to bolster its cancer diagnostics and therapeutics pipeline.
Ada Torres
Ada Torres
17 Oct 2025

Browse the archive

Full archive